Epizyme Inc (NASDAQ:EPZM) – Research analysts at Leerink Swann issued their Q1 2018 earnings per share (EPS) estimates for Epizyme in a report released on Monday. Leerink Swann analyst G. Porges forecasts that the biopharmaceutical company will earn ($0.62) per share for the quarter. Leerink Swann has a “Outperform” rating and a $22.00 price target on the stock. Leerink Swann also issued estimates for Epizyme’s Q2 2018 earnings at ($0.62) EPS, Q4 2018 earnings at ($0.57) EPS and FY2022 earnings at $3.86 EPS.
A number of other analysts also recently weighed in on the company. Cann reiterated a “buy” rating and set a $26.00 price target on shares of Epizyme in a report on Tuesday, December 12th. Zacks Investment Research downgraded Epizyme from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. BidaskClub upgraded Epizyme from a “strong sell” rating to a “sell” rating in a report on Friday, December 29th. Royal Bank of Canada downgraded Epizyme from an “outperform” rating to a “sector perform” rating and decreased their price target for the stock from $20.00 to $16.00 in a report on Thursday, November 2nd. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Epizyme in a report on Thursday, November 2nd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $22.73.
Institutional investors and hedge funds have recently modified their holdings of the company. NEA Management Company LLC grew its stake in shares of Epizyme by 3.2% in the 3rd quarter. NEA Management Company LLC now owns 6,460,851 shares of the biopharmaceutical company’s stock valued at $123,079,000 after buying an additional 200,000 shares during the period. State Street Corp grew its stake in shares of Epizyme by 59.6% in the 2nd quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock valued at $26,644,000 after buying an additional 658,727 shares during the period. University of Notre Dame DU Lac grew its stake in shares of Epizyme by 25.0% in the 3rd quarter. University of Notre Dame DU Lac now owns 191,719 shares of the biopharmaceutical company’s stock valued at $3,652,000 after buying an additional 38,368 shares during the period. Vanguard Group Inc. grew its stake in shares of Epizyme by 6.2% in the 2nd quarter. Vanguard Group Inc. now owns 3,419,844 shares of the biopharmaceutical company’s stock valued at $51,640,000 after buying an additional 200,982 shares during the period. Finally, Macquarie Group Ltd. grew its stake in shares of Epizyme by 105.5% in the 3rd quarter. Macquarie Group Ltd. now owns 41,100 shares of the biopharmaceutical company’s stock valued at $783,000 after buying an additional 21,100 shares during the period. Institutional investors own 86.04% of the company’s stock.
In other news, COO Matthew Ros sold 72,264 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $16.63, for a total value of $1,201,750.32. Following the completion of the sale, the chief operating officer now directly owns 74,867 shares in the company, valued at approximately $1,245,038.21. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 25.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Brokers Issue Forecasts for Epizyme Inc’s Q1 2018 Earnings (EPZM)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2018/02/07/brokers-issue-forecasts-for-epizyme-incs-q1-2018-earnings-epzm.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.